Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myolax is a branded generic version of tizanidine, a centrally acting muscle relaxant manufactured by Omnica Laboratories in Nepal. As a small molecule $\alpha_2$-adrenergic agonist, it is structurally related to clonidine and functions primarily at the spinal and supraspinal levels. Its mechanism involves the inhibition of excitatory interneurons, which subsequently reduces the release of excitatory neurotransmitters. Myolax is indicated for the symptomatic management of spasticity resulting from multiple sclerosis, spinal cord injury, or spinal cord disease, and is also used to treat painful muscle spasms. It is produced in 2 mg and 4 mg oral tablet formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Myolax.